CD4 and leiomyosarcoma: Conversely, PI3K/mTOR inhibition promotes infiltration and reinvigoration of exhausted PD‐1+CD8+ T cells, sustains a CD4+ Th1 niche, amplifies cytotoxic T cell responses, and sensitizes uterine leiomyosarcomas to PD‐1 blockade [480].